Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.42
AXGN's Cash to Debt is ranked higher than
55% of the 475 Companies
in the Global Medical Devices industry.

( Industry Median: 2.27 vs. AXGN: 0.42 )
AXGN' s 10-Year Cash to Debt Range
Min: 0.04   Max: No Debt
Current: 0.42

Equity to Asset -0.51
AXGN's Equity to Asset is ranked lower than
56% of the 453 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. AXGN: -0.51 )
AXGN' s 10-Year Equity to Asset Range
Min: -0.59   Max: 0.99
Current: -0.51

-0.59
0.99
F-Score: 4
Z-Score: -4.61
M-Score: -3.26
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -65.89
AXGN's Operating margin (%) is ranked higher than
53% of the 458 Companies
in the Global Medical Devices industry.

( Industry Median: 5.49 vs. AXGN: -65.89 )
AXGN' s 10-Year Operating margin (%) Range
Min: -2031.87   Max: 64.05
Current: -65.89

-2031.87
64.05
Net-margin (%) -102.13
AXGN's Net-margin (%) is ranked higher than
52% of the 458 Companies
in the Global Medical Devices industry.

( Industry Median: 3.95 vs. AXGN: -102.13 )
AXGN' s 10-Year Net-margin (%) Range
Min: -1446.15   Max: 215.68
Current: -102.13

-1446.15
215.68
ROA (%) -61.55
AXGN's ROA (%) is ranked higher than
51% of the 475 Companies
in the Global Medical Devices industry.

( Industry Median: 2.61 vs. AXGN: -61.55 )
AXGN' s 10-Year ROA (%) Range
Min: -128.2   Max: 173.62
Current: -61.55

-128.2
173.62
ROC (Joel Greenblatt) (%) -230.08
AXGN's ROC (Joel Greenblatt) (%) is ranked higher than
55% of the 473 Companies
in the Global Medical Devices industry.

( Industry Median: 8.37 vs. AXGN: -230.08 )
AXGN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -35233.33   Max: 265933.33
Current: -230.08

-35233.33
265933.33
Revenue Growth (%) 94.50
AXGN's Revenue Growth (%) is ranked higher than
99% of the 339 Companies
in the Global Medical Devices industry.

( Industry Median: 5.40 vs. AXGN: 94.50 )
AXGN' s 10-Year Revenue Growth (%) Range
Min: -74.6   Max: 477.6
Current: 94.5

-74.6
477.6
EBITDA Growth (%) -31.60
AXGN's EBITDA Growth (%) is ranked higher than
57% of the 306 Companies
in the Global Medical Devices industry.

( Industry Median: 0.60 vs. AXGN: -31.60 )
AXGN' s 10-Year EBITDA Growth (%) Range
Min: -66.5   Max: 125.9
Current: -31.6

-66.5
125.9
EPS Growth (%) -49.40
AXGN's EPS Growth (%) is ranked higher than
52% of the 297 Companies
in the Global Medical Devices industry.

( Industry Median: 2.20 vs. AXGN: -49.40 )
AXGN' s 10-Year EPS Growth (%) Range
Min: -50.5   Max: 259.3
Current: -49.4

-50.5
259.3
» AXGN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

AXGN Guru Trades in Q4 2013

Chuck Royce 12,000 sh (unchged)
» More
Q1 2014

AXGN Guru Trades in Q1 2014

Chuck Royce 12,000 sh (unchged)
» More
Q2 2014

AXGN Guru Trades in Q2 2014

Chuck Royce 12,000 sh (unchged)
» More
Q3 2014

AXGN Guru Trades in Q3 2014

Chuck Royce 12,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with AXGN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 3.41
AXGN's P/S is ranked higher than
70% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 3.40 vs. AXGN: 3.41 )
AXGN' s 10-Year P/S Range
Min: 0.3   Max: 550
Current: 3.41

0.3
550
EV-to-EBIT -7.43
AXGN's EV-to-EBIT is ranked higher than
56% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 73.45 vs. AXGN: -7.43 )
AXGN' s 10-Year EV-to-EBIT Range
Min: -224.3   Max: 99999999.99
Current: -7.43

-224.3
99999999.99
Current Ratio 8.85
AXGN's Current Ratio is ranked higher than
94% of the 474 Companies
in the Global Medical Devices industry.

( Industry Median: 2.72 vs. AXGN: 8.85 )
AXGN' s 10-Year Current Ratio Range
Min: 0.67   Max: 88.48
Current: 8.85

0.67
88.48
Quick Ratio 7.20
AXGN's Quick Ratio is ranked higher than
93% of the 474 Companies
in the Global Medical Devices industry.

( Industry Median: 1.95 vs. AXGN: 7.20 )
AXGN' s 10-Year Quick Ratio Range
Min: 0.24   Max: 88.48
Current: 7.2

0.24
88.48

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.76
AXGN's Price/Median PS Value is ranked higher than
92% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 1.21 vs. AXGN: 0.76 )
AXGN' s 10-Year Price/Median PS Value Range
Min: 0.05   Max: 120
Current: 0.76

0.05
120
Earnings Yield (Greenblatt) -13.50
AXGN's Earnings Yield (Greenblatt) is ranked higher than
51% of the 464 Companies
in the Global Medical Devices industry.

( Industry Median: 2.40 vs. AXGN: -13.50 )
AXGN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.3   Max: 6116
Current: -13.5

1.3
6116

Business Description

Industry: Medical Devices » Medical Devices
Compare: » details
AxoGen, Inc. is a regenerative medicine company with a portfolio of proprietary products and technologies for peripheral nerve reconstruction and regeneration. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body and their damage can result in the loss of function and feeling. In order to improve surgical reconstruction and regeneration of peripheral nerves the Company has developed and licensed technologies which are used in its products. Its product portfolio includes Avance Nerve Graft, which the Company believes is the first and only commercially available processed allograft nerve for bridging nerve discontinuities. AxoGuard Nerve Connector, is used as a coaptation aid to facilitate the tensionless repair of severed nerves, and AxoGuard Nerve Protector is used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. The Company's products are used by surgeons during surgical interventions to repair a wide variety of nerve injuries throughout the body. These injuries range from a simple laceration of a finger to a complex brachial plexus injury (an injury to the network of nerves that originate in the neck) as well as nerve injuries caused by dental and other surgical procedures. Avance Nerve Graft provides surgeons bridging material with the micro-architecture of a human nerve. This structure is essential and allows for bridging nerve gaps or discontinuities up to 70mm in length. Additionally, Avance Nerve Graft has product and sales synergies with AxoGuard Nerve Protector and AxoGuard Nerve Connector. AxoGuard products provide the unique features of pliability, suturability, and translucence for visualization of the underlying nerve, while also allowing the patient's own cells to incorporate into the extracellular matrix to remodel and form a tissue similar to the outermost layer of the nerve (nerve epineurium). Regenerative medical products enable the repair, restoration, replacement or regeneration of tissue or organ systems of the body. Regenerative medical products are becoming common in various medical arenas because they have been shown to be effective repairing injured or defective tissues, such as bone, tendons, dermis and other tissues of the body. AxoGen's products are subject to regulation by the FDA, as well as other federal and state regulatory bodies in the U.S. and comparable authorities in other countries.
» More Articles for AXGN

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
AXOGEN, INC. Financials Nov 21 2014
AxoGen (AXGN) Looks Good: Stock Adds 5.5% in Session Nov 17 2014
PDL BioPharma Announces Successful Conclusion of Revenue Interest Agreement with AxoGen Nov 14 2014
PDL BioPharma Announces Successful Conclusion of Revenue Interest Agreement with AxoGen Nov 14 2014
AXOGEN, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a... Nov 13 2014
AxoGen, Inc. Signs Agreement with Oberland Capital Nov 13 2014
AXOGEN, INC. Files SEC form 10-Q, Quarterly Report Nov 13 2014
AxoGen, Inc. Reports 58% Third Quarter Revenue Growth Nov 13 2014
AxoGen, Inc. to Report Third Quarter Financial Results on November 13, 2014 Nov 06 2014
AxoGen (AXGN) Shows Strength: Stock Up 15.4% in Session Oct 13 2014
AxoGen, Inc. Announces Presentation of Clinical Data for Avance(R) Nerve Graft at American Society... Sep 30 2014
Surgeon Attendance at AxoGen's Education Events Exceeds Expectations Sep 25 2014
AxoGen, Inc. to Host Surgeon Education Event at American Society for Surgery of the Hand 2014 Annual... Sep 16 2014
AxoGen, Inc. to Host Surgeon Panel on Nerve Repair at American Association of Oral and Maxillofacial... Sep 09 2014
AXOGEN, INC. Files SEC form 8-K, Change in Directors or Principal Officers Aug 25 2014
AXOGEN, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Aug 05 2014
AXOGEN, INC. Files SEC form 10-Q, Quarterly Report Aug 04 2014
AXOGEN, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 19 2014
AXOGEN, INC. Files SEC form 8-K, Change in Directors or Principal Officers May 12 2014
AxoGen's CEO Discusses Q1 2014 Results - Earnings Call Transcript Apr 30 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK